ML162, with the CAS number 1035072-16-2, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the protein kinase TBK1 (TANK-binding kinase 1). This compound is characterized by its ability to modulate cellular pathways involved in inflammation and neurodegenerative diseases. Structurally, ML162 features a unique arrangement of functional groups that contribute to its binding affinity and specificity for TBK1. The compound has been studied for its potential therapeutic applications, including its effects on autophagy and immune responses. Additionally, ML162's pharmacokinetic properties, such as solubility and stability, are essential for its efficacy in biological systems. Ongoing research continues to explore its mechanisms of action and potential uses in treating conditions like amyotrophic lateral sclerosis (ALS) and other related disorders. Overall, ML162 represents a promising avenue for drug development targeting specific kinase pathways.

ML-162 is an inhibitor of glutathione peroxidase 4 (GPX4) and decreases GPX4 levels in MDA-MB-231 breast cancer cells, as well as the viability of BT-549 breast cancer cells.

ML162

1035072-16-2: ML162, with the CAS number 1035072-16-2, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the protein kinase TBK1 (TANK-binding kinase 1). This compound is characterized by its ability to modulate cellular pathways involved in inflammation and neurodegenerative diseases. Structurally, ML162 features a unique arrangement of functional groups that contribute to its binding affinity and specificity for TBK1. The compound has been studied for its potential therapeutic applications, including its effects on autophagy and immune responses. Additionally, ML162's pharmacokinetic properties, such as solubility and stability, are essential for its efficacy in biological systems. Ongoing research continues to explore its mechanisms of action and potential uses in treating conditions like amyotrophic lateral sclerosis (ALS) and other related disorders. Overall, ML162 represents a promising avenue for drug development targeting specific kinase pathways.

ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor that induces ferroptosis. ML162 has antitumor activity. Cost-effective and quality-assured.

CAS 1035072-16-2

ML162

ML162

Ref: 54-BUP13541

ML162

Ref: TM-T8970